Name | Vernakalant Hydrochloride |
Description | Vernakalant Hydrochloride (RSD1235 hydrochloride) is a mixed voltage- and frequency-dependent Na+ and atria-preferred K+ channel blocker. |
In vitro | Block of Kv1.5 by Vernakalant Hydrochloride occurs after channel activation, as Vernakalant induces a rapid block of channel current upon depolarization with minimal resting or “tonic” block. The most significant effect is the reduction in potency at I502A, with an IC50 of 329±19 μM (n=4-10) compared to a control IC50 of 13.4±0.9 μM (n=5-23), reflecting a 25-fold potency decrease. Lesser reductions in potency, between 3- and 4-fold, were noted for V505A, I508A, T480A, and C500A. For wild-type and mutant Kv1.5 channels, IC50 for Vernakalant block are 13.35±0.93 μM, 0.61±0.03 μM, and 1.63±0.09 μM for Kv1.5 channels, Kv1.5 channelI508F, and Kv1.5 channelT479A, respectively [1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 45 mg/mL (116.6 mM), Sonication is recommended. H2O : 45 mg/mL (116.6 mM), Sonication is recommended.
|
Keywords | RSD-1235 Hydrochloride | RSD1235 Hydrochloride | Vernakalant Hydrochloride | RSD 1235 Hydrochloride |
Inhibitors Related | Minoxidil sulfate | Phenytoin sodium | Lidocaine | Valproic Acid | Lidocaine hydrochloride | L-Aspartic aicd sodium | Mebeverine hydrochloride | Amitriptyline hydrochloride | Riluzole | Indapamide |
Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |